Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx’s Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from a previous Phase 1 study of the drug were announced in September 2012.
Ablynx President and CEO Edwin Moses recently commented, “We are very pleased to move forward with our first inhaled Nanobody, which has the potential to become a first-in-class therapeutic to treat RSV infection in young children, an area with high unmet medical need. These additional studies will provide us with an appropriate clinical package for ALX-0171 that should allow the start of a Phase 2 study in infants during the second half of 2014.”
Activaero Founder and CEO Gerhard Scheuch said, “The results achieved to date in the ALX-0171 development program by our partner Ablynx are very encouraging and represent further validation not only for Ablynx’s unparalleled Nanobody technology, but also for Activaero’s FAVORITE inhalation approach. Activaero’s approach ensures efficient and pharmacoeconomically beneficial drug delivery into the lungs. In particular in children, we have shown in a Phase 2 trial in which we treated asthmatic infants that we have a highly appropriate inhalation approach with short treatment times for this fragile patient population. That’s essential for small children and infants, who are otherwise not able to focus on performing an optimal inhalation process.”
Read the Ablynx press release.
Read the Activaero press release.
